Journal of Alzheimer's Disease最新文献

{"title":"Association between late-life blood pressure and incident dementia in older men: The Kuakini Honolulu-Asia aging study.","authors":"Yuki Ogawa, Randi Chen, G Webster Ross, Timothy Donlon, Gina Fujikami, Cody Takenaka, Bradley Willcox, Kamal Masaki","doi":"10.1177/13872877261498372","DOIUrl":"https://doi.org/10.1177/13872877261498372","url":null,"abstract":"<p><p>BackgroundThe relationship between late-life blood pressure and incident dementia (including Alzheimer's disease and vascular dementia) remains controversial.ObjectiveTo examine whether late-life blood pressure is associated with incidence of dementia.MethodsWe analyzed 2649 participants aged 71 to 93 years without prevalent dementia at baseline in a prospective cohort of Japanese-American men (the Kuakini Honolulu Heart Program). Diagnosis of dementia was conducted based on standardized protocols and participants were followed for up to 20 years. Cox proportional hazards models were applied to estimate hazard ratios (HR) for incident dementia across blood pressure categories, adjusting for demographic, medical, lifestyle, and genetic factors.ResultsDuring follow-up, 716 cases of incident dementia were identified (519 cases of Alzheimer's disease and 88 cases of vascular dementia). After adjustment, high late-life systolic blood pressure (≥160 mmHg) was associated with a lower risk of Alzheimer's disease [HR 0.72 (95% confidence interval: 0.56-0.93)] and a higher risk of vascular dementia [HR 1.95 (95% confidence interval: 1.03-3.68)] compared to the reference (120 to <140 mmHg) group. The protective effect of high late-life systolic blood pressure (≥160 mmHg) on Alzheimer's disease was seen only in participants with the protective version of the <i>FOXO3</i> genotype. No significant associations were found between diastolic blood pressure and incidence of dementia.ConclusionsHigh late-life systolic blood pressure was associated with a protective effect against Alzheimer's disease, after adjusting for confounders, including the FOXO3 longevity genotype, and an increased risk of vascular dementia in older men aged over 71 years.</p>","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"13872877261498372"},"PeriodicalIF":3.4,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149194177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunoglobulin GM (γ marker) allotypes as potential genetic markers of efficacy of lecanemab therapy in Alzheimer's disease.","authors":"Janardan P Pandey","doi":"10.1177/13872877261500140","DOIUrl":"https://doi.org/10.1177/13872877261500140","url":null,"abstract":"<p><p>Lecanemab is a humanized IgG1 monoclonal antibody that targets amyloid-β (Aβ) aggregates, a pathological hallmark of Alzheimer's disease (AD). In the largest clinical trial of its kind to date, lecanemab slowed cognitive decline by 27% in patients with early-stage AD. Lecanemab has also been shown to reduce cerebral Aβ deposition. Lecanemab expresses the immunoglobulin GM 3 allotype, which is defined by an arginine residue in the CH1 region of the γ1 chain and is potentially immunogenic in individuals who lack this allotype. I hypothesize that anti-GM 3 antibodies, generated either following lecanemab administration or acquired previously through maternal-fetal incompatibility or transfusion of allotype-incompatible blood products, may form immune complexes with the therapeutic antibody. These immune complexes could be cleared by phagocytic cells, including microglia, thereby reducing the availability and efficacy of lecanemab and contributing to therapeutic nonresponsiveness. If validated, GM allotypes could serve as genetic markers for predicting response to lecanemab therapy and may help guide personalized treatment strategies in AD.</p>","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"13872877261500140"},"PeriodicalIF":3.4,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149192885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Home-delivered transcranial direct current stimulation with or without cognitive training in mild dementia due to Alzheimer's disease.","authors":"Juan C Meléndez, Joaquín Escudero, Encarnación Satorres, Iraida Delhom, Isabel Martí-Hoyos, Jesús González-Moreno","doi":"10.1177/13872877261498210","DOIUrl":"https://doi.org/10.1177/13872877261498210","url":null,"abstract":"<p><p>BackgroundTranscranial direct current stimulation (tDCS) and cognitive training are non-pharmacological interventions for cognitive impairment in Alzheimer's disease (AD), but evidence on combined protocols in mild dementia remains limited.ObjectiveTo evaluate home-delivered active tDCS combined with cognitive training and active tDCS alone versus sham tDCS in mild dementia due to AD, and explore whether the combined intervention showed changes across a broader range of cognitive outcomes.MethodsForty participants with mild dementia due to AD and evidence of amyloid-β pathology were randomized to tDCS combined with cognitive training (n = 14), active tDCS alone (n = 14), or sham tDCS (n = 12). The 10-day intervention was delivered at participants' homes by trained study personnel. Cognitive outcomes were assessed at baseline, post-intervention, and 1-month follow-up using linear mixed-effects models.ResultsSignificant Group × Time interactions were observed for the primary cognitive outcome, Mini-Mental State Examination (MMSE), and for all secondary cognitive outcomes except Backward Digit Span. Both active conditions showed greater change from baseline than sham tDCS in MMSE, Memory Alteration Test, verbal learning, total verbal recall, and delayed recall. The combined condition also showed greater change than sham tDCS in initial immediate recall and Forward Digit Span. No significant differences were observed between the two active conditions.ConclusionsActive tDCS, with or without cognitive training, was associated with more favorable short-term cognitive change than sham stimulation. The combined condition differed from sham across more outcomes, but not from active tDCS alone; therefore, this exploratory pattern does not establish a broader benefit of the combined intervention.</p>","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"13872877261498210"},"PeriodicalIF":3.4,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149192882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effective identification of cognitive impairment in primary care assisted by tablet-based digital cognitive testing.","authors":"Alexander Hanke, Cornelia McCormick, Carolin Rosendahl, Judith Tillmann, Kristin Rolke, Florian Schweizer, Leon Nissen, Lara Reimer, Stephan Jonas, Philipp Schaper, Jochen René Thyrian, Klaus Weckbecker, Michael Wagner","doi":"10.1177/13872877261486301","DOIUrl":"https://doi.org/10.1177/13872877261486301","url":null,"abstract":"<p><p>BackgroundTimely recognition of cognitive impairment and Alzheimer's disease (AD) is crucial for providing appropriate care to elderly individuals affected by these conditions. Digital short tests may help general practitioners (GPs) make more targeted referrals to specialists.ObjectiveWe studied the real-world effectiveness of a referral pathway including the digital Montreal Cognitive Assessment (MoCA Duo), administered by medical assistants (MAs) in general practitioner (GP) offices, to identify mild or major neurocognitive impairment. Ancillary studies examined the procedure's feasibility, usability, and barriers in the care pathway.MethodsTen GPs participated, one or two MAs per practice administered the MoCA Duo to patients with cognitive concerns. Patients with likely or questionable impairment were offered a referral to a memory clinic (MC) if deemed clinically appropriate. At the MC, patients received a comprehensive neuropsychological examination and a geriatric assessment.ResultsOf the 299 patients tested in GP practices (mean age: 73; 65% female), 100 achieved MoCA Duo scores in the presumably unimpaired range. 93 patients (46.73%) scoring below 27 points were referred to the MC; of those, 66 attended an appointment. 40 patients had major cognitive impairment, including 9 diagnosed with AD or vascular dementia, and 15 had mild cognitive impairment (MCI). 83.33% of patients who screened positive on the MoCA Duo at the GP practice and were assessed at the MC had at least MCI.ConclusionsDigital tests administered by MAs can help to effectively screen for cognitive impairment in primary care, supporting targeted referrals of patients with likely cognitive impairment.</p>","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"13872877261486301"},"PeriodicalIF":3.4,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149194148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cross-sectional associations of insulin resistance surrogate indices with cognitive disorders and cognitive performance in UK Biobank.","authors":"Zhinan Ye, Xiaoya Xie, Shiyue Wang, Jiawen Chen, Bo Zhang, Jiaxuan Chen, Bingxin Teng, Ruting Wei, Bohao Li, Qihan Zhang, Suwen Huang, Yiyun Weng, Dehao Yang","doi":"10.1177/13872877261494125","DOIUrl":"https://doi.org/10.1177/13872877261494125","url":null,"abstract":"<p><p>BackgroundWhile systemic insulin resistance (IR) is a well-established risk factor for Alzheimer's disease (AD), its connections to broader cognitive conditions, particularly mild cognitive impairment (MCI) and specific cognitive domains, remain unclear.ObjectiveThis study aims to explore the associations between IR surrogates and cognitive status, including AD, MCI, and normal cognition (NC) group, and to assess their association with domain-specific cognitive functions.MethodsData from 381,818 UK Biobank participants were analyzed. Logistic regression was used to assess relationships between IR surrogates-the triglyceride-glucose (TyG) index, TyG-waist-to-height ratio (TyG-WHtR), and triglyceride-to-high-density lipoprotein cholesterol (TG/HDL-C) ratio-and cognitive groups (AD, MCI, NC). Domain-specific cognitive functions, including prospective memory (PM) and reaction time (RT), were evaluated using multivariable linear regression, logistic models, and restricted cubic splines.ResultsTyG-WHtR was independently associated with MCI (adjusted odds ratio [OR] = 1.166, 95% CI: 1.084-1.255, <i>p</i> < 0.001). Elevated TG/HDL-C and TyG-WHtR were both linked to slower RT (ORs > 1, <i>p</i> < 0.05), whereas RCS analysis revealed an inverted M-shaped nonlinear association between TyG and mean RT. All IR surrogates were significantly associated with poorer PM performance (ORs < 1, <i>p</i> < 0.05).ConclusionsThis study suggests that elevated TyG-WHtR levels are independently associated with MCI. Higher TG/HDL-C and TyG-WHtR correlate with slower processing speed, with TyG showing a unique nonlinear progression. All IR indices are also associated with poorer PM performance, suggesting potential metabolic markers linked with cognitive performance.</p>","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"13872877261494125"},"PeriodicalIF":3.4,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149181869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of matrix metalloproteinases in Alzheimer's disease and small vessel disease.","authors":"Natalie Nguyen, Sophia Huynh, Barbara Mroczko, Lidia Glodzik","doi":"10.1177/13872877261494579","DOIUrl":"https://doi.org/10.1177/13872877261494579","url":null,"abstract":"<p><p>Matrix metalloproteinases (MMPs) are a family of enzymes participating in maintenance and remodeling of the extracellular matrix. Their many types are involved in diverse, sometimes contrasting physiological processes, and they are ubiquitously present throughout the CNS. In this mini-review we focused on MMP-2, MMP-3, MMP-9, and MMP-14, highlighting their importance in pathways linked to Alzheimer's disease and small vessel disease. Despite overlapping roles in modulating brain-blood barrier impairment, neuroinflammation, and the accumulation of disease-specific proteins like amyloid-β and tau, they show somewhat distinct expression patterns in different cells and differ in their primary influences on disease mechanisms. Although our knowledge is still very limited, there is evidence linking them to imaging manifestations of cerebral vessel disease and suggesting they could be a target for therapeutic interventions.</p>","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"13872877261494579"},"PeriodicalIF":3.4,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149181982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A systematic review of emotional facial expression recognition in patients with mild cognitive impairment.","authors":"Laura Alonso-Recio, Fernando Carvajal-Molina, Juan Manuel Serrano Rodríguez","doi":"10.1177/13872877261489584","DOIUrl":"https://doi.org/10.1177/13872877261489584","url":null,"abstract":"<p><p>BackgroundEmotional facial expression recognition (EFER) plays a key role in social cognition and may be compromised in mild cognitive impairment (MCI), a heterogeneous condition often considered a prodromal stage of dementia. However, evidence remains heterogeneous, and the influence of demographic, cognitive, and methodological factors is unclear.ObjectiveThis systematic review aims to synthesize recent findings on EFER performance in individuals with MCI, examining the presence and potential moderators of emotion recognition impairments.MethodsFollowing PRISMA 2020 guidelines, a systematic literature search was conducted to identify studies published between 2013 and 2025 that assessed EFER in individuals with MCI.ResultsTwenty-five studies met inclusion criteria. Most reported impaired EFER in MCI compared with healthy controls, particularly for negative emotions (anger, fear, and sadness), whereas happiness was relatively preserved. Greater impairment was observed in amnestic and multidomain MCI than in non-amnestic or single-domain forms. Findings suggested that age, educational level, global cognition and standardized emotion recognition measures may contribute to variability in EFER outcomes across studies. In contrast, evidence regarding the role of specific cognitive abilities, sex, mood, task format, stimulus exposure duration, response time constraints, and response modality was limited or inconsistent.ConclusionsOverall, evidence suggests that EFER impairments are common but heterogeneous in MCI. The variability in findings may be related to differences in cognitive profiles, sociodemographic characteristics, and methodological factors across studies. These findings support EFER as a potential indicator of socioemotional changes in prodromal dementia, although further research is needed to clarify sources of heterogeneity.</p>","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"13872877261489584"},"PeriodicalIF":3.4,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149181825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying drugs associated with Alzheimer's disease risk using machine learning-assisted signal detection.","authors":"Eeva Pylkkö, Anne Paakinaho, Sirpa Hartikainen, Valtteri Kaasinen, Anna-Maija Tolppanen","doi":"10.1177/13872877261498381","DOIUrl":"https://doi.org/10.1177/13872877261498381","url":null,"abstract":"<p><p>BackgroundSeveral Alzheimer's disease (AD) clinical trials currently focus on drug repurposing. Machine learning (ML)-based pharmacoepidemiological approaches may help identify candidate drugs for trials.ObjectiveWe applied an ML-based signal detection method to identify drugs associated with AD risk.MethodsUsing Finnish nationwide register-based data, we defined drug exposure at both subgroup and drug substance levels according to the Anatomical Therapeutic Chemical classification. Three binary embedded variables were calculated for each drug based on the frequency of dispensations over three years, starting 10 years before the index date. An algorithm combining subsampling and lasso-logistic regression was applied, with 500 replications for each drug exposure variable. Drug variables with a selection percentage (SP) ≥ 70% across replications were considered as signals. The average beta describes the direction and strength of the association.ResultsThe study population comprised 43,926 AD cases and 43,926 matched controls. The mean age was 80.3 years in both groups, and 65% of participants were women. Four drug subgroups and three individual drugs were associated with a lower risk of AD, whereas 14 subgroups and 11 individual drugs were associated with a higher risk. Drugs associated with decreased AD risk belonged to cardiovascular drugs: antihypertensives affecting the renin-angiotensin and diuretics.ConclusionsThe identified associations are consistent with established risk factors of AD and support the importance of effective hypertension management in AD prevention. Further studies are needed to evaluate whether antihypertensive drugs may exert neuroprotective effects and represent viable candidates for drug repurposing in AD.</p>","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"13872877261498381"},"PeriodicalIF":3.4,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149181975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gamma transcranial alternating current stimulation prevents scopolamine-induced damage to EEG activity and spatial memory.","authors":"Yuan Yuan, Shu Xing, Ping Ren, Zhuangfei Chen, Yu Fu","doi":"10.1177/13872877261497298","DOIUrl":"https://doi.org/10.1177/13872877261497298","url":null,"abstract":"<p><p>BackgroundDementia is a serious public health concern, primarily caused by Alzheimer's disease (AD). Transcranial alternating current stimulation (tACS) can improve cognitive function by modulating neural oscillations. While tACS shows therapeutic potential for dementia, its preventive effects remain unknown. Because tACS has long-lasting modulatory effects, we propose that these offline effects may help prevent dementia.ObjectiveThis study aims to determine whether pre-administered 40 Hz tACS prevents scopolamine-induced impairment of electroencephalogram (EEG) activity and spatial cognition. Scopolamine induces cholinergic dysfunction in animal models, mimicking AD-related behavioral and EEG abnormalities.MethodsScopolamine (3 mg/kg, i.p.) was administered to induce a mouse model of dementia. Prior to induction, tACS targeting the prefrontal cortex (PFC) and/or hippocampus (Hip) was performed for five days (40 Hz, 300 μA, 20 min/day). EEG activity was recorded from the PFC and Hip during spontaneous and task-related (Y-maze) states. In addition, spatial memory was evaluated using the Barnes maze test, and general activity including locomotion and anxiety was evaluated using the open field test.ResultsScopolamine reduced spontaneous EEG activity in gamma frequency band and task-related PFC EEG activity across multiple frequency bands. Prior Hip tACS prevented these EEG reductions. Behaviorally, scopolamine induced spatial memory deficits and increased locomotion and anxiety-like behaviors. Notably, dual-site tACS reversed memory impairment and PFC tACS reduced locomotion. In addition, tACS had little effect on anxiety.ConclusionsPrior gamma tACS exerts region-specific protection against scopolamine-induced EEG and behavioral impairments, providing first evidence for its potential as a preventive strategy for dementia-related deficits.</p>","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"13872877261497298"},"PeriodicalIF":3.4,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149181989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrative analysis of Alzheimer's disease molecular networks with circadian regulators for prioritization of drug repurposing candidates.","authors":"Alexandros Zantis, Elisa Uliassi, Chiara Pallara, Xinzhong Li","doi":"10.1177/13872877261497407","DOIUrl":"https://doi.org/10.1177/13872877261497407","url":null,"abstract":"<p><p>BackgroundAlzheimer's disease (AD) is a multifactorial neurodegenerative disorder characterized by complex molecular mechanisms. Growing evidence indicates that circadian rhythm disruption contributes to disease progression and interacts with pathogenic pathways. Although multi-omics resources, compound perturbation profiles, and pharmacological bioactivity data are increasingly available, their integrative use for drug repurposing prioritization in AD, particularly with explicit consideration of circadian rhythm, remains limited.ObjectiveThis study aimed to prioritize drug repurposing candidates for AD, by integrating heterogeneous biological and pharmacological data.MethodsWe applied an integrative, systems-level computational analysis to prioritize drug repurposing and repositioning candidates for AD by combining network-based gene prioritization, functional transcriptomic similarity analysis, and target-level bioactivity prediction. Disease-associated molecular modules were identified within the human protein-protein interaction network, with circadian rhythm regulators incorporated as an additional disease relevant biological context. These modules were represented using functional gene embeddings to rank compound perturbation signatures. Candidate compounds were subsequently refined through ligand-based bioactivity prediction across AD associated targets to support polypharmacological prioritization.ResultsThe analysis prioritized compounds supported by convergent network-level disease relevance, transcriptomic similarity, and predicted target engagement. Several drugs previously investigated in dementia-related clinical trials were recovered. Novel repositioning candidates, including PF-562271, MGCD-265, and BMS-777607, were identified, converging on focal adhesion kinase (FAK), PI3K-AKT, and receptor tyrosine kinase (RTK) signaling pathways enriched in AD-associated genes and implicated in circadian regulation and neuroinflammation.ConclusionsThis integrative analysis identifies mechanistically coherent repurposing candidates, associated with circadian and inflammatory pathways, supporting systems-based strategies for therapeutic prioritization in complex neurodegenerative diseases.</p>","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"13872877261497407"},"PeriodicalIF":3.4,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149181998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}